SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Altamira Therapeutics

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% in Altamira Therapeutics Ltd., holding 473,870 common shares.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Altamira Therapeutics Ltd.
• The Reporting Persons collectively beneficially own 473,870 common shares of Altamira Therapeutics Ltd.
• This ownership represents 9.99% of the total class of common shares.
• Both Armistice Capital, LLC and Steven Boyd hold shared voting and shared dispositive power over all 473,870 shares.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Altamira Therapeutics Ltd.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Key Dates

Keywords

Altamira Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing, Institutional Investor